Two rare disease drugs, Poteligeo (mogamulizumab, Kyowa Kirin Korea) and Livtencity (maribavir, Takeda Pharmaceuticals Korea), are likely to be added to the reimbursement list next month after completing pricing negotiations with the National Health Insurance Service.


According to industry sources on the 13th, the companies have completed pricing negotiations with the NHIS for the two drugs. Accordingly, the drugs will likely be reimbursed from April if the negotiation results are reported to the Health Insurance Policy Deliberation Committee at the end of this month.

The two drugs are both rare disease drugs that have passed the Health Insurance Review and Assessment Service's Drug Re